Advaxis Inc. Stock
Advaxis Inc. Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Advaxis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Advaxis Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advaxis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advaxis Inc. | - | - | - | - | - | - | - |
| Beximco Pharmaceuticals Ltd. GDR | -0.410% | 4.681% | 9.333% | 19.417% | 18.269% | -17.311% | -52.692% |
| SELLAS Life Sciences Group Inc | -0.780% | 7.262% | 47.463% | 112.000% | 91.498% | -17.111% | -68.813% |
| Eledon Pharmaceuticals Inc. | - | 3.846% | -8.784% | -67.548% | -66.912% | -41.304% | -90.940% |
Comments
Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for ADXS provided by MarketBeat
Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for ADXS provided by MarketBeat
Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for ADXS provided by MarketBeat